Literature DB >> 3528541

Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

R K Fuller, L Branchey, D R Brightwell, R M Derman, C D Emrick, F L Iber, K E James, R B Lacoursiere, K K Lee, I Lowenstam.   

Abstract

We conducted a controlled, blinded, multicenter study of disulfiram treatment of alcoholism in 605 men randomly assigned to 250 mg of disulfiram (202 men); 1 mg of disulfiram (204 men), a control for the threat of the disulfiram-ethanol reaction; or no disulfiram (199 men), a control for the counseling that all received. Bimonthly treatment assessments were done for one year. Relative/friend interviews and blood and urine ethanol analyses were used to corroborate patients' reports. There were no significant differences among the groups in total abstinence, time to first drink, employment, or social stability. Among the patients who drank and had a complete set of assessment interviews, those in the 250-mg disulfiram group reported significantly fewer drinking days (49.0 +/- 8.4) than those in the 1-mg (75.4 +/- 11.9) or the no-disulfiram (86.5 +/- 13.6) groups. There was a significant relationship between adherence to drug regimen and complete abstinence in all groups. We conclude that disulfiram may help reduce drinking frequency after relapse, but does not enhance counseling in aiding alcoholic patients to sustain continuous abstinence or delay the resumption of drinking.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528541

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  115 in total

1.  Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.

Authors:  K M Carroll; S A Ball; C Nich; P G O'Connor; D A Eagan; T L Frankforter; E G Triffleman; J Shi; B J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2001-08

Review 2.  Evidence-based practices for substance use disorders.

Authors:  Mark P McGovern; Kathleen M Carroll
Journal:  Psychiatr Clin North Am       Date:  2003-12

3.  Disulfiram Use in an Elderly Man With Alcoholism and Heart Disease: A Discussion.

Authors:  Jeff C. Huffman; Theodore A. Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-02

Review 4.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

5.  Riboflavin as an oral tracer for monitoring compliance in clinical research.

Authors:  V M Sadagopa Ramanujam; Karl E Anderson; James J Grady; Fatima Nayeem; Lee-Jane W Lu
Journal:  Open Biomark J       Date:  2011

6.  Cocaine sobers up.

Authors:  David Weinshenker
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

7.  Pharmacotherapy for alcohol dependence.

Authors:  Shoshana M Wortman; Amanda R Rabinowitz; David W Oslin
Journal:  Psychiatry (Edgmont)       Date:  2005-02

Review 8.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

Review 9.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 10.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.